Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1951 2
1952 4
1953 3
1955 2
1960 1
1963 1
1993 2
1994 5
1995 7
1996 8
1997 44
1998 32
1999 53
2000 86
2001 98
2002 120
2003 127
2004 178
2005 163
2006 181
2007 185
2008 210
2009 200
2010 213
2011 214
2012 210
2013 220
2014 214
2015 276
2016 274
2017 301
2018 324
2019 390
2020 504
2021 548
2022 534
2023 498
2024 201

Text availability

Article attribute

Article type

Publication date

Search Results

5,920 results

Results by year

Filters applied: . Clear all
Page 1
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Docherty KF, et al. JACC Heart Fail. 2020 Oct;8(10):800-810. doi: 10.1016/j.jchf.2020.06.020. JACC Heart Fail. 2020. PMID: 33004114 Free PMC article. Review.
This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the next 5 years, including potential new indications for use. Additionally, a practical, evidence-based approach is provided to the clinical integ …
This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the nex …
Renal protection in chronic heart failure: focus on sacubitril/valsartan.
Pontremoli R, Borghi C, Perrone Filardi P. Pontremoli R, et al. Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):445-452. doi: 10.1093/ehjcvp/pvab030. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 33822031 Free PMC article. Review.
The first-in-class angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan, has a complementary activity that counteracts the potential unwanted long-term effects of over-activation of the renin-angiotensin-aldosterone system. ...However, data on the efficacy and t …
The first-in-class angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan, has a complementary activity that counteracts the …
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
Vaduganathan M, Mentz RJ, Claggett BL, Miao ZM, Kulac IJ, Ward JH, Hernandez AF, Morrow DA, Starling RC, Velazquez EJ, Williamson KM, Desai AS, Zieroth S, Lefkowitz M, McMurray JJV, Braunwald E, Solomon SD. Vaduganathan M, et al. Eur Heart J. 2023 Aug 14;44(31):2982-2993. doi: 10.1093/eurheartj/ehad344. Eur Heart J. 2023. PMID: 37210743 Free PMC article. Clinical Trial.
AIMS: The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but was not ade …
AIMS: The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitril/valsartan vs. olmesartan (P < 0.05 for all), were also observed. Patients treated with sacubitril/valsartan achieved an

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitr …
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials.
Abdin A, Schulz M, Riemer U, Hadëri B, Wachter R, Laufs U, Bauersachs J, Kindermann I, Vukadinović D, Böhm M. Abdin A, et al. ESC Heart Fail. 2022 Dec;9(6):3737-3750. doi: 10.1002/ehf2.14097. Epub 2022 Aug 3. ESC Heart Fail. 2022. PMID: 35921043 Free PMC article. Review.
Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve quality of life, mortality, and HF hospitalizations for patients with HFrEF. The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (S/V) has an importa …
Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve quality of life, mortality, and …
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Seferovic JP, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6. Epub 2017 Mar 18. Lancet Diabetes Endocrinol. 2017. PMID: 28330649 Free PMC article. Clinical Trial.
Similarly, fewer patients were started on oral antihyperglycaemic therapy (0.77, 0.58-1.02, p=0.073) in the sacubitril/valsartan group. INTERPRETATION: Patients with diabetes and HFrEF enrolled in PARADIGM-HF who received sacubitril/valsartan had a greater long-term …
Similarly, fewer patients were started on oral antihyperglycaemic therapy (0.77, 0.58-1.02, p=0.073) in the sacubitril/valsartan grou …
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR; PARALLAX Investigators and Committee members. Pieske B, et al. JAMA. 2021 Nov 16;326(19):1919-1929. doi: 10.1001/jama.2021.18463. JAMA. 2021. PMID: 34783839 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized 1:1 either to sacubitril/valsartan (n = 1286) or to background medication-based individualized comparator (n = 1286), ie, enalapril, valsartan, or placebo stratified by prior use of a renin angiotensin system inhibitor. ...Fur …
INTERVENTIONS: Patients were randomized 1:1 either to sacubitril/valsartan (n = 1286) or to background medication-based individualize …
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators; Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Ho CY, et al. Nat Med. 2021 Oct;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4. Epub 2021 Sep 23. Nat Med. 2021. PMID: 34556856 Free PMC article. Clinical Trial.
In this study, we conducted a multi-center, double-blind, placebo-controlled phase 2 clinical trial to assess the safety and efficacy of the angiotensin II receptor blocker valsartan in attenuating disease evolution in early HCM. In total, 178 participants with early-stage …
In this study, we conducted a multi-center, double-blind, placebo-controlled phase 2 clinical trial to assess the safety and efficacy of the …
Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study.
Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Kario K, et al. J Am Heart Assoc. 2023 Apr 18;12(8):e027612. doi: 10.1161/JAHA.122.027612. Epub 2023 Apr 7. J Am Heart Assoc. 2023. PMID: 37026551 Free PMC article. Clinical Trial.
This post hoc analysis investigated the effects of sacubitril/valsartan on 24-hour BP in patients with mild-to-moderate hypertension and in patient subgroups based on nocturnal BP dipping status. ...Between-group differences in the BP control rate were greatest in the nond …
This post hoc analysis investigated the effects of sacubitril/valsartan on 24-hour BP in patients with mild-to-moderate hypertension …
Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week.
Lam CSP, Solomon SD. Lam CSP, et al. J Am Coll Cardiol. 2021 Jun 29;77(25):3217-3225. doi: 10.1016/j.jacc.2021.04.070. J Am Coll Cardiol. 2021. PMID: 34167646 Free article. Review.
Food and Drug Administration expanded indication for sacubitril/valsartan introduces a new potential taxonomy for heart failure, with no reference to "preserved" ejection fraction but referring to "below normal" ejection fraction as those most likely to benefit. ...
Food and Drug Administration expanded indication for sacubitril/valsartan introduces a new potential taxonomy for heart failure, with …
5,920 results